病例标准化疗疗效不佳，赛沃替尼为高龄 MET ex14 跳突肺癌患者带来持续获益，PFS 超 14 个

导语：赛沃替尼疗效与安全性兼顾，有效改善 MET ex14 跳突肺癌患者长期预后。

内容策划：方程

项目审核：杨静

参考文献：

[1] Drusbosky LM, et al. Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer[J]. J Hematol Oncol. 2021;14(1):129. 

[2] Lu S, et al. Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study[J]. Lancet Respir Med. 2021;9(10):1154-1164.

[3] Paik PK, et al. Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations[J]. N Engl J Med. 2020;383(10):931-943.

[4] Wolf J, et al. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer[J]. N Engl J Med. 2020;383(10):944-957.

[5] Remon J, et al. MET alterations in NSCLC-Current Perspectives and Future Challenges[J]. J Thorac Oncol. 2023;18(4):419-435.

[6] Lu S, et al. Long-Term Efficacy, Safety, and Subgroup Analysis of Savolitinib in Chinese Patients With NSCLCs Harboring MET Exon 14 Skipping Alterations[J]. JTO Clin Res Rep. 2022;3(10):100407.